 Edith Zemanick
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 73 | 2025 | 1057 | 13.780 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 20 | 2025 | 314 | 5.140 |
Why?
| | Microbiota | 13 | 2024 | 719 | 3.150 |
Why?
| | Pseudomonas Infections | 12 | 2023 | 213 | 2.940 |
Why?
| | Anti-Bacterial Agents | 24 | 2025 | 1663 | 2.810 |
Why?
| | Chloride Channel Agonists | 9 | 2025 | 78 | 2.740 |
Why?
| | Pseudomonas aeruginosa | 13 | 2023 | 336 | 2.680 |
Why?
| | Sweat | 6 | 2025 | 47 | 2.630 |
Why?
| | Chlorides | 4 | 2025 | 138 | 2.430 |
Why?
| | Quinolones | 9 | 2024 | 126 | 2.300 |
Why?
| | Aminophenols | 13 | 2025 | 145 | 2.160 |
Why?
| | Sputum | 9 | 2021 | 302 | 2.050 |
Why?
| | Indoles | 4 | 2024 | 371 | 1.630 |
Why?
| | Benzodioxoles | 9 | 2024 | 106 | 1.590 |
Why?
| | Respiratory System | 6 | 2021 | 152 | 1.450 |
Why?
| | Drug Combinations | 7 | 2024 | 323 | 1.310 |
Why?
| | Oropharynx | 3 | 2021 | 42 | 1.300 |
Why?
| | Specimen Handling | 3 | 2021 | 164 | 1.210 |
Why?
| | Metagenome | 4 | 2013 | 137 | 1.210 |
Why?
| | DNA, Bacterial | 6 | 2019 | 323 | 1.190 |
Why?
| | Lung | 9 | 2023 | 3743 | 1.090 |
Why?
| | Respiratory Tract Infections | 5 | 2024 | 372 | 1.080 |
Why?
| | Inflammation | 6 | 2017 | 2654 | 0.960 |
Why?
| | Pyrazoles | 3 | 2024 | 404 | 0.930 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 626 | 0.910 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 225 | 0.860 |
Why?
| | Child | 37 | 2025 | 20655 | 0.790 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.760 |
Why?
| | Humans | 74 | 2025 | 128417 | 0.740 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2023 | 519 | 0.700 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 332 | 0.680 |
Why?
| | Aminopyridines | 4 | 2025 | 96 | 0.670 |
Why?
| | Drug Resistance, Bacterial | 2 | 2021 | 171 | 0.650 |
Why?
| | Genetic Therapy | 4 | 2023 | 290 | 0.550 |
Why?
| | Bacteria | 8 | 2023 | 808 | 0.550 |
Why?
| | beta-Lactams | 3 | 2023 | 26 | 0.540 |
Why?
| | Adolescent | 24 | 2025 | 20179 | 0.530 |
Why?
| | Male | 38 | 2025 | 62857 | 0.510 |
Why?
| | Nasopharynx | 1 | 2016 | 67 | 0.500 |
Why?
| | Female | 39 | 2025 | 68153 | 0.490 |
Why?
| | Respiratory Function Tests | 5 | 2025 | 580 | 0.490 |
Why?
| | Carrier State | 1 | 2016 | 60 | 0.490 |
Why?
| | Lung Diseases | 3 | 2018 | 715 | 0.470 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 21 | 0.460 |
Why?
| | Vital Capacity | 1 | 2014 | 288 | 0.430 |
Why?
| | Mutation | 12 | 2023 | 3689 | 0.430 |
Why?
| | Saliva | 1 | 2015 | 207 | 0.420 |
Why?
| | Respiratory Sounds | 1 | 2014 | 120 | 0.420 |
Why?
| | Precision Medicine | 1 | 2016 | 384 | 0.390 |
Why?
| | Bronchiectasis | 1 | 2013 | 109 | 0.380 |
Why?
| | Age Factors | 2 | 2025 | 3103 | 0.380 |
Why?
| | Genotype | 3 | 2024 | 1828 | 0.370 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1020 | 0.360 |
Why?
| | Pyridines | 2 | 2024 | 475 | 0.350 |
Why?
| | Disease Progression | 6 | 2025 | 2602 | 0.340 |
Why?
| | Disease Management | 1 | 2014 | 587 | 0.340 |
Why?
| | Cytokines | 2 | 2015 | 1983 | 0.320 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1999 | 0.310 |
Why?
| | Pneumonia, Bacterial | 1 | 2009 | 109 | 0.300 |
Why?
| | Adult | 15 | 2025 | 35299 | 0.300 |
Why?
| | Infant | 7 | 2023 | 8914 | 0.290 |
Why?
| | Young Adult | 11 | 2025 | 12312 | 0.280 |
Why?
| | Child, Preschool | 11 | 2025 | 10384 | 0.280 |
Why?
| | Biofilms | 2 | 2020 | 241 | 0.280 |
Why?
| | Clinical Trials as Topic | 3 | 2024 | 993 | 0.280 |
Why?
| | Quinolines | 2 | 2024 | 153 | 0.260 |
Why?
| | Treatment Outcome | 9 | 2025 | 10151 | 0.250 |
Why?
| | Oxygen | 2 | 2020 | 899 | 0.240 |
Why?
| | Meconium Ileus | 1 | 2024 | 5 | 0.240 |
Why?
| | Prospective Studies | 7 | 2023 | 7036 | 0.240 |
Why?
| | Endpoint Determination | 1 | 2024 | 75 | 0.210 |
Why?
| | Fetal Diseases | 1 | 2024 | 156 | 0.210 |
Why?
| | Olfaction Disorders | 1 | 2023 | 60 | 0.210 |
Why?
| | Central Venous Catheters | 1 | 2023 | 47 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 119 | 0.200 |
Why?
| | Catheter-Related Infections | 1 | 2023 | 67 | 0.200 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 212 | 0.200 |
Why?
| | Advisory Committees | 1 | 2024 | 218 | 0.200 |
Why?
| | C-Reactive Protein | 1 | 2025 | 397 | 0.200 |
Why?
| | Catheterization, Peripheral | 1 | 2023 | 104 | 0.190 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 23 | 0.190 |
Why?
| | Quality Improvement | 3 | 2019 | 1094 | 0.190 |
Why?
| | Catheterization, Central Venous | 1 | 2023 | 97 | 0.190 |
Why?
| | Trachea | 1 | 2023 | 221 | 0.190 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 2019 | 77 | 0.180 |
Why?
| | Quality of Life | 3 | 2023 | 2680 | 0.180 |
Why?
| | Venous Thrombosis | 1 | 2023 | 161 | 0.180 |
Why?
| | Tobramycin | 3 | 2023 | 50 | 0.180 |
Why?
| | Staphylococcal Infections | 2 | 2016 | 379 | 0.180 |
Why?
| | Pseudomonas | 2 | 2022 | 28 | 0.170 |
Why?
| | Respiratory System Agents | 1 | 2020 | 22 | 0.160 |
Why?
| | Bacteriological Techniques | 1 | 2019 | 68 | 0.160 |
Why?
| | Luminescent Measurements | 1 | 2019 | 78 | 0.160 |
Why?
| | International Cooperation | 1 | 2019 | 171 | 0.160 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2024 | 375 | 0.160 |
Why?
| | Genetic Variation | 2 | 2021 | 933 | 0.150 |
Why?
| | Critical Pathways | 1 | 2019 | 79 | 0.150 |
Why?
| | Bacterial Infections | 1 | 2020 | 226 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2020 | 248 | 0.150 |
Why?
| | Delphi Technique | 1 | 2019 | 221 | 0.150 |
Why?
| | Alleles | 1 | 2021 | 844 | 0.150 |
Why?
| | Infant, Newborn | 4 | 2024 | 5687 | 0.150 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 77 | 0.150 |
Why?
| | Immunoglobulin A | 1 | 2019 | 201 | 0.140 |
Why?
| | United States | 5 | 2024 | 13830 | 0.140 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2018 | 126 | 0.140 |
Why?
| | Case-Control Studies | 4 | 2019 | 3328 | 0.140 |
Why?
| | Safety | 1 | 2019 | 327 | 0.140 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2019 | 204 | 0.140 |
Why?
| | Blood Proteins | 1 | 2019 | 239 | 0.140 |
Why?
| | Volatile Organic Compounds | 1 | 2018 | 54 | 0.140 |
Why?
| | Pilot Projects | 2 | 2023 | 1563 | 0.140 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 6 | 0.140 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 29 | 0.140 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 38 | 0.130 |
Why?
| | Azithromycin | 2 | 2023 | 91 | 0.130 |
Why?
| | Respiratory Mucosa | 1 | 2019 | 304 | 0.130 |
Why?
| | Consensus | 1 | 2019 | 613 | 0.130 |
Why?
| | Rifampin | 1 | 2017 | 84 | 0.130 |
Why?
| | Foundations | 1 | 2016 | 24 | 0.130 |
Why?
| | Cohort Studies | 2 | 2017 | 5388 | 0.130 |
Why?
| | Patient Selection | 1 | 2019 | 663 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2710 | 0.120 |
Why?
| | Cholesterol Esters | 1 | 2015 | 7 | 0.120 |
Why?
| | Pulmonary Medicine | 1 | 2016 | 80 | 0.120 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 430 | 0.120 |
Why?
| | Bronchi | 1 | 2016 | 240 | 0.120 |
Why?
| | Regression Analysis | 1 | 2017 | 978 | 0.120 |
Why?
| | Radiography | 1 | 2017 | 859 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2019 | 843 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2019 | 1848 | 0.120 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 35 | 0.120 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 36 | 0.120 |
Why?
| | Staphylococcus | 1 | 2015 | 74 | 0.120 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2019 | 354 | 0.120 |
Why?
| | Administration, Oral | 3 | 2023 | 754 | 0.110 |
Why?
| | Achromobacter denitrificans | 1 | 2014 | 1 | 0.110 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2014 | 2 | 0.110 |
Why?
| | Spirometry | 1 | 2015 | 251 | 0.110 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.110 |
Why?
| | Forced Expiratory Volume | 3 | 2020 | 509 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2023 | 14454 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1484 | 0.110 |
Why?
| | Chronic Disease | 1 | 2019 | 1705 | 0.110 |
Why?
| | Biomarkers | 5 | 2020 | 3880 | 0.110 |
Why?
| | Genetic Markers | 1 | 2014 | 338 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 384 | 0.100 |
Why?
| | Leukocyte Elastase | 1 | 2012 | 74 | 0.100 |
Why?
| | Proteomics | 1 | 2019 | 1009 | 0.100 |
Why?
| | Animals | 4 | 2019 | 34479 | 0.100 |
Why?
| | Feces | 1 | 2015 | 435 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2023 | 661 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 771 | 0.100 |
Why?
| | Proteolysis | 1 | 2012 | 162 | 0.090 |
Why?
| | Middle Aged | 4 | 2023 | 30889 | 0.090 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 17 | 0.090 |
Why?
| | Biota | 1 | 2011 | 35 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 2213 | 0.090 |
Why?
| | Phenotype | 1 | 2019 | 3044 | 0.090 |
Why?
| | Neonatal Screening | 1 | 2012 | 163 | 0.090 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 575 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3232 | 0.080 |
Why?
| | Morbidity | 1 | 2009 | 301 | 0.080 |
Why?
| | Blood Glucose | 1 | 2018 | 2093 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1478 | 0.070 |
Why?
| | Pediatrics | 1 | 2016 | 1046 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5039 | 0.070 |
Why?
| | Gastrointestinal Microbiome | 1 | 2015 | 633 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2014 | 4892 | 0.060 |
Why?
| | Pyrrolidines | 1 | 2024 | 68 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 1936 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3020 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2023 | 74 | 0.050 |
Why?
| | Anaerobiosis | 1 | 2021 | 57 | 0.050 |
Why?
| | Aged | 1 | 2021 | 21953 | 0.050 |
Why?
| | Styrenes | 1 | 2020 | 4 | 0.040 |
Why?
| | Colistin | 1 | 2020 | 8 | 0.040 |
Why?
| | Porphyrins | 1 | 2020 | 21 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2020 | 24 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 166 | 0.040 |
Why?
| | Serologic Tests | 1 | 2019 | 50 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 101 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 116 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2019 | 117 | 0.040 |
Why?
| | Homozygote | 1 | 2018 | 192 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 126 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 279 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 356 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 122 | 0.030 |
Why?
| | Minocycline | 1 | 2016 | 27 | 0.030 |
Why?
| | Chlorhexidine | 1 | 2016 | 24 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2721 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 64 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 42 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 500 | 0.030 |
Why?
| | Nanoparticles | 1 | 2020 | 368 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 186 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 357 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 171 | 0.030 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 7 | 0.030 |
Why?
| | Telemedicine | 1 | 2024 | 782 | 0.030 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2015 | 29 | 0.030 |
Why?
| | Permeability | 1 | 2015 | 156 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 860 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 275 | 0.030 |
Why?
| | Decision Making | 1 | 2019 | 847 | 0.030 |
Why?
| | Genetic Carrier Screening | 1 | 2012 | 25 | 0.030 |
Why?
| | Trypsinogen | 1 | 2012 | 10 | 0.020 |
Why?
| | Blotting, Western | 1 | 2015 | 1164 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2012 | 115 | 0.020 |
Why?
| | Pregnancy | 1 | 2024 | 6357 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1390 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 5362 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3772 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2016 | 823 | 0.020 |
Why?
| | Proteins | 1 | 2015 | 932 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 41 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 158 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 9704 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2819 | 0.010 |
Why?
|
|
Zemanick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|